There are some highly promising diabetes treatments entering the market that investors should know about.
News & Analysis: Eli Lilly and Company
The big pharma company made all the right moves in 2018.
The biopharma delivered the goods with its drug pipeline, scored marketing approval for its lead drug candidate, and agreed to be acquired for $8 billion.
Shares jumped more than 66% in response to news that the company is being acquired. Here's what investors need to know.
One of the largest pharma companies in the world moved to boost its cancer immunotherapy pipeline.
Shares skyrocket in response to accepting a takeover offer from Eli Lilly.
The stock cratered after the drugmaker reported bummer news from an important late-stage clinical trial.
The biotech giant's stock price declined Wednesday after competitor Eli Lilly reported disappointing results from a late-stage clinical trial for a potential Alzheimer's treatment.
Shares fall by double digits in response to disappointing news from an important clinical trial.
Another costly late-stage failure with its Alzheimer's disease candidate is upsetting, but the market might be overreacting.
Changes to agreements with Eli Lilly and Novartis' sparked investor enthusiasm for the use of Jakafi in graft versus host disease.